Distinguished Visiting Chair

---

 

 

EDUCATION AND POSITIONS HELD:

• B.S. & M.S., Chemistry, National Tsing Hua University, Taiwan, 1966-1972
• Ph.D., Cell and Developmental Biology, Harvard University, 1973-1977
• Postdoctoral Fellow, Center for Cancer Research, M. I. T., 1977-1980
• Supervisor of Cellular Immunology, Ortho Pharmaceutical Corp., 1980-1981
• Director of Immunology, V. P. of Research, Centocor, Inc., 1981-1985
• Professor of Molecular Virology, Baylor College of Medicine, 1986-1991
• Cofounder 1986, and V.P. of R & D, 1986-1996, Tanox, Inc., Houston
• Professor 1996-2003; Dean 1996-1999; Tsing Hua Professor of Life Science 2003-2006; College of Life Science, National Tsing Hua University
• President, Development Center for Biotechnology, Taipei, 2000-2003
• Distinguished Professor, Genomics Research Center, Academia Sinica, 2006-2015
• Distinguished Visiting Chair, Genomics Research Center, Academia Sinica, 2016-present

HONORS:

• Foundation for the Advancement of Outstanding Scholarship Award, 1997-2002
• Appointed Science and Technology Advisor of the Executive Yuan, 2002-2006
• Xolair (Chang's anti-IgE invention) approved by FDA, USA, 2003
• Appointed Tsing Hua Professor of Life Science, 2003-2006
• "Honorary Fellow Award" from American College of Allergy, Asthma, and Immunology (ACAAI), 2004
• Nature Biotechnology's shortlist of personalities who made the most significant contribution to biotech in the past 10 years. Nature Biotechnology 24, 291-300, 2006
• Xolair chosen for Prix Galien Award for outstanding innovation in R&D, UK, 2006
• "Honorary Fellow Award" from American Academy of Allergy, Asthma, and Immunology (AAAAI), 2007
• "Father of Xolair" plaque from Novartis, in Middle East Asthma and Allergy Conference, Dubai, 2012
• "Lifetime Achievement Award in Allergy" from Taiwan Academy of Pediatric Allergy, Asthma and Clinical Immunology, 2013
• TWAS(The World Academy of Sciences) Prize in Medical Sciences, 2014

RESEARCH INTERESTS:

New drug discovery and antibody engineering

The main focus of our group is to develop humanized antibody-based and immunogen-based therapeutics, which target key molecules involved in IgE-mediated allergic pathway. We are also developing new technology platforms for improved antibody engineering. One such program is to develop humanized antibody against CεmX domain in human membrane-bound IgE, for the purpose of controlling IgE-expressing B lymphocytes. CεmX, discovered by our group, is a 52 a.a. domain with a unique sequence. Anti-CεmX, if successfully developed, may be used in combination with an anti-IgE antibody, such as omalizumab (trade name Xolair), which is also derived from Dr. Chang's invention and which is approved for allergic asthma.

SELECTED PUBLICATIONS:

• Chang TW, Chen C, Lin CJ, Metz M, Church MK, Maurer M, 2015, “The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria.”, The Journal of allergy and clinical immunology, 135(2), 337-342.e2. (SCIE)
• Chu HM, Wright J, Chan YH, Lin CJ, Chang TW & Lim C, 2014, “Two potential therapeutic antibodies bind to a peptide segment of membrane-bound IgE in different conformations.”, Nature communications, 5, 3139. (SCIE)
• Chen JB, Wu PC, Hung AF, Chu CY, Tsai TF, Yu HM, Chang HY, Chang TW, 2010, “Unique epitopes on C epsilon mX in IgE-B cell receptors are potentially applicable for targeting IgE-committed B cells.”, Journal of immunology, 184(4), 1748-1756. (SCIE)
• Chang TW & Pan AY, 2008, “Cumulative environmental changes, skewed antigen exposure, and the increase of allergy.”, Advances in immunology, 98, 39-83. (SCIE)
• Chang TW, Wu PC, Hsu CL, Hung AF, 2007, “Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases.”, Advances in immunology, 93, 63-119. (SCIE)
• Chang TW & Shiung YY, 2006, “Anti-IgE as a mast cell-stabilizing therapeutic agent.”, The Journal of allergy and clinical immunology, 117(6), 1203-1212. (SCIE)
• Chang TW, 2000, “The pharmacological basis of anti-IgE therapy.”, Nature biotechnology, 18(2), 157-162. (SCIE)